The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

This was the stock's third consecutive day of gains.

We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are ...

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $402.49, representing a -1.13% change from its previous close.

The FDA will decide later this month whether to approve a novel drug for acute pain that could offer a nonaddictive ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Artivion, Inc. AORT: This medical device and tissue ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Fintel reports that on January 3, 2025, Raymond James downgraded their outlook for Vertex (NasdaqGM:VERX) from Outperform to ...

Like its competitors, Google continues to experiment with low- and no-code tools that harness agentic AI for business ...